Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 18/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.41 |
| ▸ | KDR | P35968 | 2/20 | 0.41 |
| ▸ | INSR | P06213 | 1/20 | 0.41 |
| ▸ | PLK4 | O00444 | 1/20 | 0.40 |
| ▸ | PAK4 | O96013 | 1/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL220024 | 0.88 | JAK2 (0.47) | IGF1RJAK2JAK3FGFR1KDR | |
| SCHEMBL217975 | 0.86 | IGF1R (0.45) | IGF1RFGFR1KDRINSRPLK4 | |
| SCHEMBL4064988 | 0.85 | JAK2 (0.43) | IGF1RJAK2JAK3FGFR1PLK4 | |
| SCHEMBL4033781 | 0.81 | IGF1R (0.57) | IGF1RJAK2JAK3FGFR1KDR | |
| SCHEMBL56940 | 0.81 | PIN1 (0.48) | IGF1RJAK2JAK3PLK4PAK4 | |
| SCHEMBL219273 | 0.79 | IGF1R (0.62) | IGF1RJAK2JAK3FGFR1KDR | |
| SCHEMBL4308621 | 0.79 | JAK2 (0.35) | IGF1RJAK2JAK3FGFR1PLK4 | |
| SCHEMBL3933207 | 0.79 | NTRK1 (0.50) | IGF1RJAK2JAK3FGFR1KDR | |
| SCHEMBL4065934 | 0.79 | PLK4 (0.40) | IGF1RJAK2JAK3FGFR1PLK4 | |
| SCHEMBL3349448 | 0.77 | JAK2 (0.75) | IGF1RJAK2JAK3FGFR1PLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101346371-B | 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer | ASTRAZENECA AB | 2012-11-14 | — | — | CN | disclosed |
| EP-1945631-B1 | 4- (3-AMINOPYRAZOLE) PYRIMIDINE DERIVATIVES FOR USE AS TYROSINE KINASE INHIBITORS IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2012-08-08 | — | — | EP | disclosed |
| US-20120071480-A1 | 4-(3-AMINOPYRAZOLE) PYRIMIDINE DERIVATIVES FOR USE AS TYROSINE KINASE INHIBITORS IN THE TREATMENT OF CANCER | ASTRAZENECA R&D (SE) | 2012-03-22 | — | — | US | disclosed |
| US-8088784-B2 | 4-(3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer | ASTRAZENECA AB (SE) | 2012-01-03 | — | — | US | disclosed |
| EP-2388259-A1 | 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer | AstraZeneca AB (SE) | 2011-11-23 | — | — | EP | disclosed |
| US-8040733-B2 | Non-volatile memory device and method of operating the same | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2011-10-18 | — | — | US | disclosed |
| US-20100160325-A1 | 4-(3-AMINOPYRAZOLE) PYRIMIDINE DERIVATIVES FOR USE AS TYROSINE KINASE INHIBITORS IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2010-06-24 | — | — | US | disclosed |
| CN-101501030-A | Pyrimidine derivatives useful in the treatment of cancer | ASTRAZENECA AB (SE) | 2009-08-05 | — | — | CN | disclosed |
| EP-2044063-A1 | PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | Astra Zeneca AB (SE) | 2009-04-08 | — | — | EP | disclosed |
| CN-101346371-A | 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer | ASTRAZENECA AB (SE) | 2009-01-14 | — | — | CN | disclosed |
| US-20080287475-A1 | 4-(3-Aminopyrazole) Pyrimidine Derivatives for Use as Tyrosine Kinase Inhibitors in the Treatment of Cancer | ASTRAZENECA AB (SE) | 2008-11-20 | — | — | US | disclosed |
| CN-101238116-A | Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2008-08-06 | — | — | CN | disclosed |
| EP-1945631-A1 | 4- (3-AMINOPYRAZOLE) PYRIMIDINE DERIVATIVES FOR USE AS TYROSINE KINASE INHIBITORS IN THE TREATMENT OF CANCER | AstraZeneca AB (SE) | 2008-07-23 | — | — | EP | disclosed |
| WO-2008001070-A1 | PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | WO | disclosed |
| US-20080004302-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | US | disclosed |
| WO-2007049041-A1 | 4- (3-AMINOPYRAZOLE) PYRIMIDINE DERIVATIVES FOR USE AS TYROSINE KINASE INHIBITORS IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287475-A1 | 4-(3-Aminopyrazole) Pyrimidine Derivatives for Use as Tyrosine Kinase Inhibitors in the Treatment of Cancer | ABL1, FLT3, ERBB2 | IGF1R 818/4885JAK2 35/4885JAK3 13/4885 |
| US-20120071480-A1 | 4-(3-AMINOPYRAZOLE) PYRIMIDINE DERIVATIVES FOR USE AS TYROSINE KINASE INHIBITORS IN THE TREATMENT OF CANCER | ABL1, FLT3, ERBB2 | IGF1R 784/4885JAK2 42/4885JAK3 14/4885 |
| US-20100160325-A1 | 4-(3-AMINOPYRAZOLE) PYRIMIDINE DERIVATIVES FOR USE AS TYROSINE KINASE INHIBITORS IN THE TREATMENT OF CANCER | ABL1, FLT3, ERBB2 | IGF1R 818/4885JAK2 35/4885JAK3 13/4885 |
| US-20080004302-A1 | Novel Compounds | CYP11B2, CYP11B1, CYP46A1 | IGF1R 3217/4885JAK2 2137/4885JAK3 3642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.